United States: Capitol Hill Healthcare Update

The chairman of a Senate healthcare committee outlined a key test for stabilizing the Affordable Care Act's (ACA) shaky individual marketplace: Both Republicans and Democrats will have to give a little.

That formula has been wildly unsuccessful not only this year but also in recent years as the two parties have been at loggerheads over the GOP's efforts to repeal the ACA. But in the wake of Senate Republicans' failed efforts this summer to replace the healthcare law, HELP Committee Chairman Lamar Alexander (R-Tenn.) said last week there is a bipartisan path forward.

He said Republicans would need to guarantee future cost-sharing payments to insurers in an effort to stabilize the law's individual insurance marketplace. In return, Democrats would need to permit new regulatory flexibility for states to design their own coverage within the confines of the ACA.

Alexander's committee held two days of hearings last week with testimony from state insurance commissioners, and three Republican and two Democratic governors.

Alexander said he wants Congress to vote on a plan this month, ahead of a deadline by insurers to finalize contracts for next year. He said lawmakers' quick action last week passing a short-term government funding bill and legislation raising the debt ceiling opened the door for a healthcare bill to win congressional passage before September 30.

Senate Majority Leader Mitch McConnell (R-Ky.) said he doubts Democrats could support relaxing standards enough to win over Republican backing for continuing the insurance subsidy payments. Even if senators accepted a compromise, it is uncertain whether it could win approval in the House or whether President Trump would sign it into law.

GOP Senators Expected to Introduce ACA Replacement Bill

Two Republican senators say they will introduce legislation today that would repeal the ACA's individual and employer mandate penalties and transform the law's Medicaid expansion into a trillion-dollar block grant for states to design their own coverage models.

President Trump wants Congress to take another stab an overhauling the healthcare law and senior White House officials are pinning their hopes on new legislation by Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.). The bill would also strip some of the ACA's provider taxes, such as the excise tax on medical device manufacturers, but leave other taxes in place.

Cassidy said his bill would use fast-track budget reconciliation legislation, which allows Republicans to sidestep a filibuster and pass the bill with only 50 votes, instead of the usual 60 votes. But that fast-track procedure expires September 30, the end of the 2017 fiscal year.

The Congressional Budget Office will likely need at least two weeks to produce an economic analysis of the Graham-Cassidy bill – a critical first step before the Senate could even schedule a vote. That leaves little time this month before the expiration of the reconciliation legislation.

House Panel Questions Hospitals on 340B Use

Leaders on the House Energy and Commerce Committee last week sent letters to nearly two dozen hospitals and health systems nationwide seeking information on their participation in the 340B drug pricing program.

The committee has been examining the program for most of the year. During a hearing earlier this summer, officials with the federal agency that administers the program – the Health Services and Resources Administration – could not say to what degree hospitals were passing on program savings to patients.

Full committee Chairman Greg Walden (R-Ore.) and Oversight and Investigations Subcommittee Chairman Tim Murphy (R-Pa.) fired off the letters Friday seeking information on hospitals' 340B purchased drugs. Specifically, the committee wants data on how organizations use any 340B program savings to aid vulnerable populations, including charity care to uninsured and underinsured patients.

Entities nationwide that received inquiries from the committee included Cedars-Sinai Medical Center, Duke University Health System, Grady Memorial Hospital, Johns Hopkins Hospital, Massachusetts General Hospital, and Parkland Health and Hospital System.

Hatch Open to Long-Term CHIP Reauthorization

Senate Finance Committee Chairman Orrin Hatch (R-Utah) agreed with witnesses at a hearing last week who called for a five-year renewal of the Children's Health Insurance Program (CHIP).

Hatch, who helped write the law in 1997, told reporters after the hearing that he could support a longer-term extension. But a longer renewal would also increase the likelihood Hatch's committee considers CHIP program changes. A shorter-term extension would likely only continue existing policies while extending program funding.

The federal-state program expires September 30, but a federal commission said states are not expected to exhaust CHIP funds before the end of the year. So it's unclear when Congress will act on CHIP legislation, but lawmakers don't appear to be in a hurry to meet the deadline this month – neither Hatch nor House leaders has introduced CHIP legislation.

The CHIP program itself is largely non-controversial, and congressional leaders want to keep its reauthorization free from extraneous items, such as stabilizing the ACA's individual insurance markets. As with pairing hurricane relief funding with legislation raising the debt ceiling, Congress may seek to add contentious items that could not pass on their own to a CHIP renewal bill.

Pharmacists Battle Each Other Over House Amendment

The House last week defeated an effort backed by a group of pharmacy compounders that opponents say would have risked triggering another outbreak like the one in 2012 caused by contaminated steroid injections that killed 64 people and injured hundreds of others nationwide.

Rep. Buddy Carter (R-Ga.) offered an amendment to the FDA's annual appropriations bill that would have blocked the agency from finalizing a congressionally mandated draft 2015 memorandum of understanding on the interstate sale of compounded drugs.

The issue pitted 503A compounding pharmacies against 503B outsourcing facilities, with each group known for a section of the Drug Quality and Security Act that Congress passed in response to the 2012 meningitis outbreak at the New England Compounding Center. Under that law, 503A pharmacies can compound to individual prescriptions while 503B outsourcing facilities can produce large batches of drugs with or without prescriptions that are sold to healthcare facilities for office use only.

Carter – himself a pharmacist who owns a Georgia pharmacy – backed the 503A compounders' effort to expand their capabilities; the FDA's draft memo would have limited the 503A compounders' role. Carter's amendment was defeated 141-279.

The National Community Pharmacists Association and the International Academy of Compounding Pharmacists advocated for Carter's amendment, while the Outsourcing Facilities Association and Pew Charitable Trusts opposed what they said was an effort to undermine the Drug Quality Security Act.

Senate Panel Backs Health Funding Bill

The Senate Appropriations Committee last week overwhelmingly approved a fiscal 2018 funding bill that includes $79.4 billion for health agencies and programs administered by the U.S. Department of Health and Human Services (HHS).

The funding would be $1.7 billion higher than current fiscal 2017 funding and $2.2 billion higher than the House's version of the HHS spending bill. The Senate bill won committee approval 30-1.

Of the $36 billion approved for the National Institutes of Health (NIH), the committee allocated $290 million for precision medicine studies, $1.9 billion for Alzheimer's research and $400 million for the BRAIN initiative.

The committee never seriously considered President Trump's call to reduce NIH spending by 22 percent, which the White House proposed earlier this year in a budget request to Congress. Instead, the senators increased NIH funding by $2 billion.

Congress last week approved a stopgap funding bill to keep the government open, extending 2017 spending levels for 70 days into fiscal 2018, which starts October 1. That makes December 8 the new deadline for lawmakers to approve funding to keep the government open, including HHS.

Sanders to Introduce Single-payer Health Bill

While Republicans remain flummoxed by healthcare policy and politics, Democrats are split on whether to support the ACA or back a more aggressive government role in healthcare.

Sen. Bernie Sanders (I-Vt.) this week is scheduled to introduce a single-payer healthcare bill dubbed "Medicare for all."

Sanders made single-payer a cornerstone of his 2016 presidential campaign, and he is trying to position the issue as a touchstone for Democrats considering running for president in 2020. Sens. Elizabeth Warren (D-Mass.) and Kamala Harris (D-Calif.) recently announced they would back Sanders' bill.

Companion legislation introduced in the House by Rep. John Conyers (D-Mich.) has 117 co-sponsors – about 60 percent of all House Democrats.

Separately, Sen. Chris Murphy (D-Conn.) – another potential 2020 Democratic presidential contender – is preparing legislation that would allow individuals and businesses to buy into Medicare from the ACA's Exchanges.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.